Novel drug - dinutuximab for high-risk neuroblastoma
Neuroblastoma is the most common extracranial tumor in children aged <5 years. Prognosis of high-risk neuroblastoma is not good even after use of aggressive chemotherapy. Newer drug anti-GD2 monoclonal antibodies, dinutuximab in combination with granulocyte-macrophage colony-stimulating factor or in...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publishing
2018-01-01
|
| Col·lecció: | Apollo Medicine |
| Matèries: | |
| Accés en línia: | http://www.apollomedicine.org/article.asp?issn=0976-0016;year=2018;volume=15;issue=3;spage=132;epage=134;aulast=Kushwah |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|